Advanced Accelerator's Lutathera meets in Phase III

Advanced Accelerator Applications S.A. (Saint Genis Pouilly, France) said Lutathera (177Lu-DOTA0-Tyr3-octreotate) met its primary endpoint in the Phase III NETTER-1 trial to treat midgut neuroendocrine tumors.

The company said Lutathera significantly improved progression-free survival compared with a double dose of Sandostatin LAR Depot octreotide acetate. The trial included patients with inoperable, progressive, somatostatin receptor positive tumors. ...